Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease
- PMID: 20405005
- PMCID: PMC2854133
- DOI: 10.1371/journal.pone.0009893
Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease
Erratum in
- PLoS One. 2010;5(4). doi:10.1371/annotation/38a101d6-a1f2-4a74-ab63-bc5c61e5f62b
Abstract
Background: Pituitary corticotroph tumors secrete excess adrenocorticotrophic hormone (ACTH) resulting in Cushing's disease (CD). Standard treatment includes surgery and, if not successful, radiotherapy, both of which have undesirable side effects and frequent recurrence of the tumor. Pharmacotherapy using PPARgamma agonists, dopamine receptor agonists, retinoic acid or somatostatin analogs is still experimental. Curcumin, a commonly used food additive in South Asian cooking, has potent growth inhibitory effects on cell proliferation. Our laboratory recently demonstrated that curcumin inhibited growth and induced apoptosis in prolactin- and growth hormone-producing tumor cells. Subsequently, Schaaf et.al. confirmed our findings and also showed the in vivo effectiveness of curcumin to suppress pituitary tumorigenesis. However the molecular mechanism that mediate this effect of curcumin are still unknown.
Principal findings: Using the mouse corticotroph tumor cells, AtT20 cells, we report that curcumin had a robust, irreversible inhibitory effect on cell proliferation and clonogenic property. The curcumin-induced growth inhibition was accompanied by decreased NFkappaB activity. Further, curcumin down-regulated the pro-survival protein Bcl-xL, depolarized the mitochondrial membrane, increased PARP cleavage, which led to apoptotic cell death. Finally, curcumin had a concentration-dependent suppressive effect on ACTH secretion from AtT20 cells.
Conclusion: The ability of curcumin to inhibit NFkappaB and induce apoptosis in pituitary corticotroph tumor cells leads us to propose developing it as a novel therapeutic agent for the treatment of CD.
Conflict of interest statement
Figures




Similar articles
-
Targeting the ERK pathway for the treatment of Cushing's disease.Oncotarget. 2016 Oct 25;7(43):69149-69158. doi: 10.18632/oncotarget.12381. Oncotarget. 2016. PMID: 27708250 Free PMC article.
-
AT-101 acts as anti-proliferative and hormone suppressive agent in mouse pituitary corticotroph tumor cells.J Endocrinol Invest. 2018 Feb;41(2):233-240. doi: 10.1007/s40618-017-0733-8. Epub 2017 Jul 20. J Endocrinol Invest. 2018. PMID: 28730425
-
Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.Mol Cell Endocrinol. 2014 Aug 25;394(1-2):37-46. doi: 10.1016/j.mce.2014.07.001. Epub 2014 Jul 8. Mol Cell Endocrinol. 2014. PMID: 25011056
-
The role of somatostatin analogs in Cushing's disease.Pituitary. 2004;7(4):257-64. doi: 10.1007/s11102-005-1404-x. Pituitary. 2004. PMID: 16132202 Review.
-
PPAR-gamma in Cushing's disease.Pituitary. 2004;7(4):265-9. doi: 10.1007/s11102-005-1430-8. Pituitary. 2004. PMID: 16416039 Review.
Cited by
-
Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.Pituitary. 2015 Aug;18(4):542-53. doi: 10.1007/s11102-014-0607-4. Pituitary. 2015. PMID: 25280813
-
Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells.PLoS One. 2013 May 7;8(5):e62773. doi: 10.1371/journal.pone.0062773. Print 2013. PLoS One. 2013. PMID: 23667519 Free PMC article.
-
Cushing's syndrome: from physiological principles to diagnosis and clinical care.J Physiol. 2015 Feb 1;593(3):493-506. doi: 10.1113/jphysiol.2014.282871. Epub 2015 Jan 5. J Physiol. 2015. PMID: 25480800 Free PMC article. Review.
-
Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells.J Neurochem. 2014 Jun;129(5):781-91. doi: 10.1111/jnc.12645. Epub 2014 Jan 23. J Neurochem. 2014. PMID: 24372287 Free PMC article.
-
Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):69-88. doi: 10.1007/s00210-024-03347-6. Epub 2024 Aug 5. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39102032 Review.
References
-
- Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001;54:183–188. - PubMed
-
- Ross EJ, Linch DC. Cushing's syndrome–killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646–649. - PubMed
-
- Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, et al. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest. 2004;27:1055–1059. - PubMed
-
- Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94:115–122. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials